Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
We will discuss the industry trends by examining the pipeline by company, therapeutic area, disease, target and drug type, using data from Pharma Intelligence’s Phamaprojects. This report will focus on research and development as it is now, how it is changing and mutating, and where it has been headed during 2016 and will be in 2017.
Join Alex Shimmings, Executive Editor, Europe, Commercial, Scrip, Pink Sheet, In Vivo and Ian Lloyd, Senior Director, Pharmaprojects and Data Integration - Citeline
as they will share insight on the following key areas:
Total pipeline size – the pharma forest is teeming with life
The 2017 pipeline by phase – Baby boom leads the way, but growth throughout the family
Top companies – Big beasts still dominate, but Novartis is the new king of the jungleTop therapies – Cancer’s herds spread further into the pharma habitat
Types of pipeline drugs – As biologicals proliferate, is the small molecule becoming a dinosaur?
Mechanisms and Targets – how to stay alive in a crowded ecosystem
Survival of the fittest – Darwinian forces mean pharma’s creatures must find their niches
Datamonitor Healthcare: data analysis and insight, Pharmapro...
In previous years, delegates at the American Society for Clinical Oncology (ASCO) annual meeting had been treated to exciting clinical data from anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies such as Kymriah (tisagenlecleucel; Novartis), Yescarta (axicabtagene ciloleucel; Gilead), and various pipeline assets in advanced hematologic malignancies.
The discovery and deep investigation of the microbiome has been one of the most significant recent biomedical advances. Extensive research suggests that dysbiosis of the gut microbiome plays a significant role in multiple gastrointestinal (GI) disorders such as; Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS).
To build and maintain gold-standard, next generation R&D intelligence tools, Sitetrove, Trialtrove, Pharmaprojects, and Trialpredict have been undergoing a major program of investment. In addition to the many new and exciting changes on the horizon, the robust and reliable Citeline tools that you use to inform your business decisions will formally join Informa’s Pharma Intelligence family of brands.
Sitetrove: Clinical trial site & investigator identification
Approximately 400,000 investigators in over 170 countries, all with clinical trial experience, all at your fingertips. Support your trial success and inform your principal investigator (PI) and site selection activities with Sitetrove, now on a sleek, modern interface for simpler, faster and more efficient searching.